ERBB3 and neoplasm: HER3 expression on baseline tumor tissue samples was examined in 15 available samples (two from the brain and 13 from extra-CNS sites) and assessed to evaluate whether there was correlation with efficacy endpoints (ORR, CBR, DCR, PFS and OS).